美国联邦贸易委员会主席Jon Leibowitz注意到,制药商们千方百计地为产品增加后续专利,以延缓保护的失效,但其实那些专利没什么价值。
Another tactic is pay-for-delay , in which a drugmaker facing a legal challenge to itspatent pays its would-be competitor to put off introducing its cheaper copy.
另一种战术是 有偿延迟 协议,也就是说在专利诉讼时,制药企业会付给未来竞争对手一笔钱,以延迟价钱更低的仿制药进入市场。
In the year to October the FTC identified what it believes to be 28 such settlements.
截止到10月,FTC就发现了28起类似事件。
American and European regulators are looking into these deals.
美国和欧洲的监管部门也开始调查这些协议。
However, legal challenges against them have faltered, and a bill to ban them is stuck inCongress.
然而,反对这些协议的诉讼一再搁浅,而美国国会也未能通过禁止此类事件的一项法案。
To encourage generics makers to challenge patents on drugs, and introduce cheapercopies,
为了鼓励非专利制药企业挑战药品专利、生产价钱更低的仿制药,
an American law passed in 1984 says that the first one to do so will get a 180-day exclusivityperiod,
【2015考研英语阅读制药企业悬念】相关文章:
最新
2016-10-18
2016-10-11
2016-10-11
2016-10-08
2016-09-30
2016-09-30